❮ Back to Researchers

Raphael Schneider

MD, PhD, FRCPC, CIP

Investigator, Li Ka Shing Knowledge Institute

Tel: (416) 864-5377
Email: raphael.schneider@unityhealth.to
Twitter: @raph_schneider

Research Programs

Labs

Schneider Lab ❯

Biography

Dr. Raphael Schneider is a neurologist and researcher working in the BARLO MS Centre at St. Michael’s Hospital. He is an assistant professor at the University of Toronto in both the Department of Medicine and the Institute of Medical Science. He completed a Ph.D. in the Department of Laboratory Medicine and Pathobiology (neuroscience) at the University of Toronto, focusing on extracellular vesicles as biomarkers in neurological diseases and a postdoctoral fellowship in neuroimmunology at the Université de Montréal where he studied the role of CD8+ T lymphocytes in multiple sclerosis (MS). Before joining the MS group at St. Michael’s Hospital, Dr. Schneider completed the Clinical Investigator Program of the Royal College of Physicians and Surgeons of Canada supported by a Phillipson Clinician-Scientist scholarship.

Dr. Schneider’s primary research focus is finding new blood and spinal fluid biomarkers for people with MS. He is particularly interested in early diagnosis and estimation of prognosis. He has recently been awarded a Slamen-Fast New Initiatives in Neurology Award and a Medical Research Grant from the J.P. Bickell Foundation.

Recent Publications

  1. Park, C, Weerakkody, JS, Schneider, R, Miao, S, Pitt, D. CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases. Front Neurosci. 2024;18 :1426700. doi: 10.3389/fnins.2024.1426700. PubMed PMID:38966760 PubMed Central PMC11222337.
  2. Lim, TR, Suthiphosuwan, S, Micieli, J, Vosoughi, R, Schneider, R, Lin, AW et al.. Low-Field (64mT) Portable MRI for Rapid Point-of-Care Diagnosis of DIS in Patients Presenting with Optic Neuritis. AJNR Am J Neuroradiol. 2024; :. doi: 10.3174/ajnr.A8395. PubMed PMID:38926091 .
  3. Ucciferri, CC, Gower, A, Alvarez-Sanchez, N, Whetstone, H, Ramaglia, V, Gommerman, JL et al.. Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis. J Vis Exp. 2024; (204):. doi: 10.3791/65738. PubMed PMID:38465945 .
  4. Welsh, JA, Goberdhan, DCI, O'Driscoll, L, Buzas, EI, Blenkiron, C, Bussolati, B et al.. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13 (2):e12404. doi: 10.1002/jev2.12404. PubMed PMID:38326288 PubMed Central PMC10850029.
  5. Schneider, R, Brand-Arzamendi, K, Reynold Lim, T, Lee, LE, Guenette, M, Suthiphosuwan, S et al.. Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome. Mult Scler. 2024;30 (2):156-165. doi: 10.1177/13524585231219131. PubMed PMID:38145319 .
  6. Chertcoff, A, Schneider, R, Azevedo, CJ, Sicotte, N, Oh, J. Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis. Neurol Clin. 2024;42 (1):15-38. doi: 10.1016/j.ncl.2023.06.008. PubMed PMID:37980112 .
  7. Martin, SJ, Schneider, R. Multiple sclerosis and exercise-A disease-modifying intervention of mice or men?. Front Neurol. 2023;14 :1190208. doi: 10.3389/fneur.2023.1190208. PubMed PMID:37885474 PubMed Central PMC10598461.
  8. Rotstein, D, Schneider, R. A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis. Neurology. 2023;101 (5):197-198. doi: 10.1212/WNL.0000000000207605. PubMed PMID:37290973 .
  9. Lee, S, Muccilli, A, Schneider, R, Selchen, D, Krysko, KM. Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. Mult Scler. 2023;29 (4-5):595-605. doi: 10.1177/13524585231154780. PubMed PMID:36840605 PubMed Central PMC9969223.
  10. Kim, ST, Muñoz-Grajales, C, Dunn, SE, Schneider, R, Johnson, SR, Touma, Z et al.. Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther. 2023;25 (1):21. doi: 10.1186/s13075-023-02997-w. PubMed PMID:36765391 PubMed Central PMC9912609.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Department of Medicine, University of Toronto
  • Assistant Professor, Institute of Medical Science, University of Toronto